Share-based Payment Arrangement, Expense of MAXCYTE, INC. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MAXCYTE, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • MAXCYTE, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,954,000, a 42% decline year-over-year.
  • MAXCYTE, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $11,641,000, a 14% decline year-over-year.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2024 was $13,083,000, a 6.4% decline from 2023.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2023 was $13,979,000, a 19% increase from 2022.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2022 was $11,752,000, a 48% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MAXCYTE, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $11,641,000 $1,954,000 -$1,416,000 -42% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $13,057,000 $3,514,000 -$50,000 -1.4% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $13,107,000 $3,039,000 +$24,000 +0.8% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $13,083,000 $3,134,000 -$440,000 -12% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $13,523,000 $3,370,000 -$239,000 -6.6% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $13,762,000 $3,564,000 +$45,000 +1.3% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $13,717,000 $3,015,000 -$262,000 -8% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $13,979,000 $3,574,000 +$455,800 +15% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $13,523,200 $3,609,000 +$410,400 +13% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $13,112,800 $3,519,000 +$546,200 +18% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $12,566,600 $3,277,000 +$814,600 +33% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $11,752,000 $3,118,200 +$669,800 +27% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $11,082,200 $3,198,600 +$913,200 +40% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $10,169,000 $2,972,800 +$1,067,600 +56% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $9,101,400 $2,462,400 +$1,142,600 +87% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $7,958,800 $2,448,400 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $2,285,400 +$1,687,400 +282% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $1,905,200 +$1,346,200 +241% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $1,319,800 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q3 2020 $598,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $559,000 01 Apr 2020 30 Jun 2020 10-Q 13 Sep 2021 2021 Q2

MAXCYTE, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $13,083,000 -$896,000 -6.4% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $13,979,000 +$2,227,000 +19% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $11,752,000 +$3,793,200 +48% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $7,958,800 +$5,487,000 +222% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $2,471,800 +$719,700 +41% 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
2019 $1,752,100 01 Jan 2019 31 Dec 2019 10-K 22 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.